CD22 and neoplasm: In the murine xenograft model, CD22-CAR/CD19-engager NK cells recognized tumor cells in an antigen-dependent manner, redirected T cells to tumor cells, and caused significant leukemia regression (Szoor et al., 2017 J Immunol [193]).